Pharmaceutical Outsourcing covers news of importance to the contract services segment of the pharmaceutical industry.
Collected from the most trusted on-line resources, these news stories are chosen and published here based on their relevance to the pharmaceutical industry.
Topics of interest typically include: mergers and acquisitions, service additions, new capabilities, personnel changes, news from the FDA and other international regulatory and standard-setting agencies, and new outsourcing contracts and deals.
If you are looking to stay up-to-date with the news in your industry, this resource is vital for your industry knowledge.
Cardinal Health announced that construction has begun for a new 350,000 square-foot logistics center in Columbus, Ohio, that will serve as a centralized replenishment center for the distribution of over-the-counter consumer health products in support...
read more
Arch Biopartners Inc. announced that three additional clinical sites in Turkey have joined the Phase II trial for LSALT peptide targeting the prevention and treatment of cardiac surgery-associated acute kidney injury (CS-AKI).
read more
Abzena, an end-to-end integrated CDMO for complex biologics and bioconjugates, announced a significant expansion of their Bristol, PA bioconjugate development and cGMP manufacturing site.
read more
Aragen, a Contract Research Development and Manufacturing Organization (CRDMO) for small molecules and biologics, announced that it has operationalized the first phase of its biologics manufacturing facility in Bangalore, India through its 100% ...
read more
PCI Pharma Services has released its first Environmental, Social & Governance (ESG) Report. A detailed overview of PCI's multifaceted sustainability journey, the report showcases the strides taken from the program's formal inception in 2021 through ...
read more
Wednesday, March 27, 2024
Recipharm, a global leader in contract development and manufacturing, has announced two major milestones as part of its ongoing commitment to sustainability, underpinning the Group’s pledge to minimize its environmental impact.
read more
SMC Ltd announced the acquisition of an end-to-end fill/finish facility in Charlotte, North Carolina. The facility enables SMC to offer a wider portfolio of services to its pharma clients including lab to market development, analytical services, ...
read more
Veeda Clinical Research Limited announced that it has acquired Heads, a privately held European CRO, which specializes in conducting clinical trials in oncology. Established in 2010, Heads has operational presence in 25 multiple strategically ...
read more
Exothera has launched its nucleic acids service offering, powered by their continuous-batch RNA production platform, Ntensify™. Developed by Exothera sister company Quantoom Biosciences, the Ntensify™ platform fast-tracks the production of higher ...
read more
Andelyn Biosciences, Inc., a cell and gene therapy Contract Development and Manufacturing Organization (CDMO), has partnered with Grace Science, LLC, to tech transfer and manufacture GS-100, a suspension process AAV NGLY1 gene therapy for Phase I/II/...
read more
Charles River Laboratories International, Inc. and National University of Singapore’s (NUS) Yong Loo Lin School of Medicine (NUS Medicine), a leading medical education institution with a world-renowned medical research field of stem cell biology and ...
read more
Wednesday, March 20, 2024
Paradigm Clinical Research, a clinical research site business, announced the opening of its flagship clinic in San Diego, California, coinciding with the celebration of the company’s 15th anniversary.
read more
SCHOTT Pharma plans to make Wilson, North Carolina home to its newest site. The investment is supported by $21 million in state and local incentive awards and will expand SCHOTT Group’s presence in the United States, a strategic market in its growth ...
read more
Specialist Biometrics CRO, Veramed, announced the appointment of Karen Curran as Chief Strategy Officer at Veramed. Karen joins during a period of substantial global growth for the company.
read more
Johnson & Johnson announced that the FDA Oncologic Drugs Advisory Committee (ODAC) recommends CARVYKTI® (ciltacabtagene autoleucel, cilta-cel) for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least...
read more